|
Nintedanib (n = 332)
|
Placebo (n = 331)
|
---|
≥ 1 restricted or prohibited therapy
|
53 (16.0)
|
91 (27.5)
|
Glucocorticoidsa
|
44 (13.3)
|
72 (21.8)
|
Mycophenolate mofetil
|
9 (2.7)
|
9 (2.7)
|
Azathioprine
|
4 (1.2)
|
6 (1.8)
|
Tacrolimus
|
4 (1.2)
|
5 (1.5)
|
Ciclosporin
|
1 (0.3)
|
6 (1.8)
|
Rituximab
|
3 (0.9)
|
2 (0.6)
|
Cyclophosphamide
|
0 (0.0)
|
3 (0.9)
|
Nintedaniba
|
0 (0.0)
|
3 (0.9)
|
Pirfenidonea
|
2 (0.6)
|
1 (0.3)
|
- Data are n (%) of subjects who took ≥ 1 such therapy at baseline, during treatment with trial drug, and/or following discontinuation of trial drug (up to week 52) for any duration. Glucocorticoids were only counted as restricted therapies if used at high dose (> 20 mg/day prednisone or equivalent) and if the route of administration was oral, intravenous, intravenous bolus, intravenous drip, or intramuscular. Other therapies are displayed regardless of dose or route of administration
- aBased on customized drug grouping; for other therapies, preferred names are shown